Nano-X Imaging Ltd.
HealthcareNASDAQ:NNOX · NASDAQ Global Market
+$0.05 today
Vol 0.66M · Avg 1.45M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-53.7%
avg 10.7%
ROIC
-39.7%
avg 15.1%
ROA
-46.3%
avg -58.7%
Analysis
ROIC is currently the strongest return metric at -39.7% versus its period average of 15.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Erez I. Meltzer | Chief Executive Officer & Acting Chairman of the Board | $1.32M | — | 69 | $17,544.00 | 0.03% |
Ran Daniel | Chief Financial Officer | $542,081.00 | — | 58 | $46,424.00 | 0.07% |
James Dara | GM of Source & Services Division and Head of Nanox USA | $423,046.00 | — | 56 | $39,474.00 | 0.06% |
Ofir Koren | General Manager of Nanox.ARC Division | $387,248.00 | — | 56 | $39,474.00 | 0.06% |
Tamar Aharon Cohen | Executive Vice President & Chief Marketing Officer | $353,584.00 | — | 49 | $39,474.00 | 0.06% |
Ilung Kim | Head of Nanox Korea | $300,000.00 | — | 67 | — | — |
Gali Yahav Attias | Chief of Corporate Resources | — | — | 47 | $39,474.00 | 0.06% |
Marina Gofman Feler | Chief Legal Officer | — | — | 37 | $26,316.00 | 0.04% |
Orit Wimpfheimer | Chief Medical Officer & Vice President of Product Nanox AI | — | — | 55 | — | — |
Elli Yuz | Chief Executive Officer OF USARAD Holdings Inc. | — | — | — | — | — |
Michael Yuz | President & CMO, USARAD Holdings Inc. | — | — | — | $17,544.00 | 0.03% |
Mike Cavanaugh | IR-ICR Westwicke | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$3,650.00
Sells
0
$0.00
Net Sentiment
+$3,650.00
Net buying
Most Active
Daniel Ran
1 transactions
Analysis
Insiders reported 1 buys worth $3,650.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3,650.00. Daniel Ran was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +52.5% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +52.5% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Inogen, Inc.
NASDAQ:INGN
$173.28M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
Health Catalyst, Inc.
NASDAQ:HCAT
$136.70M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Solana Company
NASDAQ:HSDT
$89.92M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
Who manages NNOX?
Nano-X Imaging Ltd. (NNOX) lists 12 active executives. The top listed executive is Gali Yahav Attias, Chief of Corporate Resources.
Are NNOX insiders buying or selling?
Recent insider activity shows net buying of $3,650.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.